sexta-feira, 13 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 4, 2026

B&G Foods outlines $1.655B–$1.695B sales target for 2026 as portfolio transformation accelerates

View original at seekingalpha.com
B&G Foods outlines $1.655B–$1.695B sales target for 2026 as portfolio transformation accelerates Earnings Call Insights: B&G Foods (BGS) Q4 2025 MANAGEMENT VIEW * Kenneth Keller, President, CEO & Director, opened by announcing a major portfolio reshaping milestone, stating the divestiture of the Green Giant U.S…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Based on 2026 guidance, adjusted diluted earnings per share expected to be in range of $0.55 to $0.65

    80% confidence
  • The divestiture of Green Giant U.S. frozen business is the largest piece in portfolio transformation that should result in stronger focus, simplification, greater synergies and higher margins across core shelf-stable business lines

    80% confidence
  • Base business trends on remaining core Meals, Spices & Flavor Solutions and Specialty businesses expected to improve plus 0.4% versus last year

    80% confidence
  • Net result of divestitures and acquisition will deliver more focused portfolio expected to generate positive adjusted EBITDA growth, stronger cash flows, lower working capital intensity, reduced leverage and higher gross and adjusted EBITDA margins

    80% confidence
  • Company is moving towards leverage targets but not there yet

    80% confidence
  • 4% quarter-to-date base business growth attributed to both weather-driven baking staples demand and lapping last year's trade inventory reduction

    80% confidence
  • Q4 2025 generated $539.6 million in net sales, net loss of $15.2 million or $0.19 per diluted share, adjusted net income of $22.8 million or $0.28 per adjusted diluted share, $84.7 million in adjusted EBITDA and adjusted EBITDA as percentage of net sales of 15.7%

    80% confidence
  • Spices and seasonings has been pretty resilient and posting good numbers, part of gradual improvement in U.S. food retail consumption

    80% confidence
  • Q4 base business net sales improved to down approximately 2.4% compared to down 2.7% in Q3

    80% confidence
  • Seneca co-pack agreement has cost-plus structure ensuring profitability

    80% confidence
  • Company is on way to 4.5x to 5.5x long-term leverage target but still has more work to do

    80% confidence
  • Company will spend very similar amount in 2026 on brand support as in 2025, with different portfolio allocation and probable increase in spending on a few brands

    80% confidence
  • Green Giant U.S. frozen business was not the right fit due to seasonal production, geographic complexity, and high working capital intensity

    80% confidence
  • Proceeds from divestitures would be used to fund new acquisitions

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
B&G Foods outlines $1.655B–$1.695B sales target for 2026 as portfolio transformation accelerates — Source | Via News | pt.VIA.NEWS